Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010-2011 to 2016-2017.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
19 11 2020
Historique:
received: 05 05 2020
accepted: 20 05 2020
pubmed: 23 5 2020
medline: 15 12 2020
entrez: 23 5 2020
Statut: ppublish

Résumé

Influenza vaccine effectiveness against influenza and noninfluenza respiratory viruses (NIRVs) was assessed by test-negative design using historic datasets of the community-based Canadian Sentinel Practitioner Surveillance Network, spanning 2010-2011 to 2016-2017. Vaccine significantly reduced the risk of influenza illness by >40% with no effect on coronaviruses or other NIRV risk.

Identifiants

pubmed: 32442261
pii: 5842161
doi: 10.1093/cid/ciaa626
pmc: PMC7314125
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2285-2288

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Vaccine. 2020 Jan 10;38(2):350-354
pubmed: 31607599
Lancet. 1982 Feb 27;1(8270):502
pubmed: 6121154
Euro Surveill. 2009 Oct 08;14(40):
pubmed: 19822124
Clin Infect Dis. 2012 Jun;54(12):1778-83
pubmed: 22423139
Pediatr Infect Dis J. 2020 May;39(5):355-368
pubmed: 32310621
Clin Infect Dis. 2013 Sep;57(6):789-93
pubmed: 23748138
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Euro Surveill. 2013 Sep 12;18(37):
pubmed: 24079398

Auteurs

Danuta M Skowronski (DM)

British Columbia Centre for Disease Control, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Macy Zou (M)

British Columbia Centre for Disease Control, Vancouver, Canada.

Quinten Clarke (Q)

British Columbia Centre for Disease Control, Vancouver, Canada.

Catharine Chambers (C)

British Columbia Centre for Disease Control, Vancouver, Canada.

James A Dickinson (JA)

University of Calgary, Calgary, Canada.

Suzana Sabaiduc (S)

British Columbia Centre for Disease Control, Vancouver, Canada.

Romy Olsha (R)

Public Health Ontario, Toronto, Canada.

Jonathan B Gubbay (JB)

Public Health Ontario, Toronto, Canada.
University of Toronto, Toronto, Canada.

Steven J Drews (SJ)

Provincial Laboratory for Public Health, Edmonton, Canada.
University of Alberta, Edmonton, Canada.

Hugues Charest (H)

Institut National de Santé Publique du Québec, Quebec City, Canada.

Anne-Luise Winter (AL)

Public Health Ontario, Toronto, Canada.

Agatha Jassem (A)

British Columbia Centre for Disease Control, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Michelle Murti (M)

Public Health Ontario, Toronto, Canada.
University of Toronto, Toronto, Canada.

Mel Krajden (M)

British Columbia Centre for Disease Control, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Gaston De Serres (G)

Institut National de Santé Publique du Québec, Quebec City, Canada.
Laval University, Quebec City, Canada.
Centre Hospitalier Universitaire de Québec, Quebec City, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH